Therapeutic area intelligence for Lupus Nephritis with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 1

Companies

Regeneron →

Assets

Lupus Nephritis →

Rituximab →

Viatris →

Recent signals(3)

ClinicalJuly 10, 2026

Regeneron initiates dose escalation study of bispecific antibodies for Lupus Nephritis

Regeneron Pharmaceuticals is conducting a dose escalation study of bispecific antibodies in adult participants with Lupus Nephritis.

ClinicalJuly 1, 2026

Rituximab and Low-Dose Mycophenolate Mofetil Trial for Pediatric Lupus Nephritis

A clinical trial is underway to evaluate the efficacy and safety of rituximab combined with low-dose mycophenolate mofetil for treating proliferative lupus nephritis in children.

ClinicalJune 22, 2026

Viatris Initiates Trial for Cenerimod in Active Lupus Nephritis

A clinical trial is underway to assess the efficacy and safety of cenerimod for treating active lupus nephritis in adults.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.